Featured Research

from universities, journals, and other organizations

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

July 16, 2013
Weill Cornell Medical College
Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.

Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in Boston, Mass. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.

IVIG is a mixture of antibodies derived from the blood of healthy donors. Given its ability to control infection and inflammation, IVIG has been used to treat disease for more than 30 years. It has been approved for use in treating several disorders, ranging from pediatric immune disorders to a blood cancer and Kawasaki disease, but is not approved for Alzheimer's disease.

The Gammaglobulin Alzheimer's Partnership (GAP) Study was a Phase 3, randomized, double-blind, placebo-controlled clinical trial in 390 people with mild to moderate Alzheimer's disease, conducted at 45 centers in the U.S. and Canada. Two different doses of IVIG were tested versus placebo as add-ons to approved Alzheimer's medications. The drug was administered every two weeks for 18 months. Primary study endpoints were changes on two well-established tests of cognition and daily functioning -- the ADAS-Cog and ADCS-ADL.

In a topline announcement in May, the GAP researchers reported negative results on the GAP study's primary outcomes -- the ADAS-Cog and ADCS-ADL. At the same time, preliminary observations were reported on favorable changes on another cognitive test, the Modified Minimental State Examination (3MS) in two subgroups: people with Alzheimer's who carried the APOE-e4 Alzheimer's risk gene, and those who were moderately impaired. The study was not powered to show statistical significance in these pre-planned subgroup analyses.

Today at the AAIC meeting, Dr. Relkin reported for the first time on additional cognitive and biomarker tests that shed further light on the study's outcomes. The researchers found that study participants in the APOE-e4 carrier subgroup receiving IVIG 400mg/kg/2wk (n=87) had numerically superior results at 18 months relative to placebo on the Modified Mini-Mental State (3MS) Examination (n=66) and the Trails B test (n=77), two out of several measures of thinking ability made in the study. "Though 3MS and Trails B were not the primary outcome measures in the study, they are well-established cognitive measures." Dr. Relkin says.

Biomarker analyses demonstrated that antibodies from the treatment reached the central nervous system. Among the findings that Dr. Relkin reported:

  • A statistically significant, dose dependent reduction in plasma beta-amyloid 42 levels (but not beta-amyloid 40) was observed in IVIG treated patients relative to placebo.
  • Statistically significant, dose dependent increases in anti-oligomer and anti-fibril antibodies in the CSF or plasma occurred in IVIG-treated patients relative to placebo.
  • A reduction in brain fibrillar amyloid (as measured by PET scan using florbetapir) was seen in patients who received IVIG at the 400mg/kg/2wk dose, particularly those who were APOE-e4 carriers.
  • No effect in tau and phosphorylated tau levels in spinal fluid.

"It is important to say that the GAP study results do not provide grounds for prescribing IVIG in Alzheimer's disease, even with this positive signal in the APOE-e4 carriers," Dr. Relkin says. "Further confirmatory studies and regulatory approval would be needed before clinical use could be recommended."

"The primary clinical outcomes are unequivocally negative, but there are intriguing signals in the clinical and biological markers," he adds "With the understanding that we cannot draw conclusions about IVIG's effectiveness in these subgroups from these results alone, the effects of IVIG on beta-amyloid and antibody levels in the blood and brain are noteworthy. These results support that IVIG can target beta amyloid and that the antibodies it contains can reach the brains of people with Alzheimer's when administered through the bloodstream."

Despite the negative results of the Phase 3 IVIG trial, and because of the successes of IVIG in animal models of Alzheimer's and early stage trials in people, researchers continue to pursue how IVIG may work in the brain to inform ongoing Alzheimer's therapy research.

"The favorable data in subjects who carry the APOE-e4 gene also underscores the need for further research and emphasis on a precision medicine approach to Alzheimer's," Dr. Relkin says. "The APOE-e4 carrier group is easily identified by genetic testing. It may be important to more specifically target our next generation of Alzheimer's therapies with an eye towards treating identifiable subgroups of patients such as APOE-e4 carriers."

Earlier Phase Studies at Weill Cornell Showed Promise of IVIG

Dr. Relkin is associate professor of clinical neurology at Weill Cornell Medical College and study leader of the Gammaglobulin Alzheimer's Partnership (GAP) trial, conducted by Baxter International and the Alzheimer's Disease Cooperative Study (ADCS), a clinical trial consortium supported by the United States National Institute on Aging in the National Institutes of Health.

Dr. Relkin, who is also director of the Memory Disorders Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and a researcher in Weill Cornell's Feil Family Brain and Mind Research Institute, became interested in IVIG when he and Weill Cornell colleagues Dr. Mark Weksler and Dr. Paul Szabo found evidence in 2003 of decreased levels of free antibodies against beta amyloid in the blood of patients with Alzheimer's disease. Following a report by German investigator Dr. Richard Dodel that IVIG contained increased levels of anti-amyloid antibodies, they began testing IVIG as a potential anti-amyloid immunotherapy for Alzheimer's disease.

For example, Dr. Relkin reported in 2006 that a pilot study found IVIG stabilized or improved cognitive function in Alzheimer's patients when administered over a period of a year or more. When the treatment stopped, cognitive abilities began to decline, and then stabilized once more when the treatment was offered again.

A 2007 laboratory analysis by Dr. Relkin and his colleagues demonstrated that antibodies in IVIG could not only recognize and scoop up toxic beta amyloid proteins, but also other proteins that accumulate in a wide variety of neurodegenerative diseases.

Phase2 GAP results demonstrated that patients who responded best to IVIG did not measurably decline in cognitive abilities over 18 months and had an average rate of brain shrinkage similar to elderly individuals who did not have the disease. Dr. Relkin presented these findings in April 2010 at the annual meeting of the American Academy of Neurology.

Dr. Relkin proposed the GAP trial after the earliest phase studies he carried out showed the promise of IVIG in slowing dementia-related decline. The Phase 1 and Phase 2 trials he performed involved relatively small numbers of patients, however, making the generalizability of the findings uncertain. He proposed the GAP study as a means of assessing IVIG's safety and effectiveness in a larger number of Alzheimer's patients.

"The Phase 3 GAP study was conducted at a very high standard, setting goals that have not yet been reached by any medication for Alzheimer's disease that is approved or under investigation," Dr. Relkin says. "What we stand to learn from this research cannot be overstated. The data reinforces some of the findings from the earlier phases of the GAP study, and we need now to delve deeper into the data to help move forward toward improving the treatment of Alzheimer's disease."

Story Source:

The above story is based on materials provided by Weill Cornell Medical College. Note: Materials may be edited for content and length.

Cite This Page:

Weill Cornell Medical College. "Updated results from Phase 3 trial of IVIG for Alzheimer's disease." ScienceDaily. ScienceDaily, 16 July 2013. <www.sciencedaily.com/releases/2013/07/130716092743.htm>.
Weill Cornell Medical College. (2013, July 16). Updated results from Phase 3 trial of IVIG for Alzheimer's disease. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/07/130716092743.htm
Weill Cornell Medical College. "Updated results from Phase 3 trial of IVIG for Alzheimer's disease." ScienceDaily. www.sciencedaily.com/releases/2013/07/130716092743.htm (accessed July 31, 2014).

Share This

More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


    Free Subscriptions

    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile

    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?

    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins